Evidence map›Paper›PMID 28482786›Full record

ReviewCurrent Alzheimer research2017

Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective.

Javed Ahmad, Sohail Akhter, Md Rizwanullah, Mohammad Ahmed Khan, Lucie Pigeon, Richard T Addo, Nigel H Greig, Patrick Midoux, Chantal Pichon, Mohammad Amjad Kamal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current Alzheimer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Neurotheranostics as personalized medicines.Advanced drug delivery reviews · 2019
    Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Javed AhmadDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, UP- 229010. India.
Sohail AkhterLE STUDIUM® Loire Valley Institute for Advanced Studies, Centre-Val de Loire Region, Orleans, France.
Md RizwanullahDepartment of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi-110062. India.
Mohammad Ahmed KhanDepartment of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, New Delhi-110062. India.
Lucie PigeonNucleic acids transfer by non viral methods, Centre de Biophysique Moleculaire, CNRS UPR4301, Orleans, France.
Richard T AddoUnion University, School of Pharmacy Room 149 Providence Hall, 1050 Union University Drive, Jackson, TN 38305. United States.
Nigel H GreigDrug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National, Institute on Aging, National Institutes of Health, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224. United States.
Patrick MidouxNucleic acids transfer by non viral methods, Centre de Biophysique Moleculaire, CNRS UPR4301, Orleans, France.
Chantal PichonNucleic acids transfer by non viral methods, Centre de Biophysique Moleculaire, CNRS UPR4301, Orleans, France.
Mohammad Amjad KamalNovel Global Community Educational Foundation. Australia.

Funding

Design And Development Of Experimental Therapeutics ((Systemic & Neurodegenerative Disorders and Alzheimer's Disease)ZIAAG000311 · NIA · NATIONAL INSTITUTE ON AGING · PI GREIG, NIGEL H. · 2009 to 2025
$16.0M
Intramural NIH HHS Z99 AG999999
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD), a cognitive dysfunction/dementia state amongst the elders is characterized by irreversible neurodegeneration due to varied pathophysiology. Up till now, anti-AD drugs having different pharmacology have been developed and used in clinic. Yet, these medications are not curative and only lowering the AD associated symptoms. Improvement in treatment outcome required drug targeting across the blood-brain barrier (BBB) to the central nervous system (CNS) in optimal therapeutic concentration. Nanotechnology based diagnostic tools, drug carriers and theranostics offer highly sensitive molecular detection, effective drug targeting and their combination. Over the past decade, significant works have been done in this area and we have seen very remarkable outocome in AD therapy. Various nanoparticles from organic and inorganic nanomaterial category have successfully been investigated against AD.

conclusionThis paper discussed the role of nanoparticles in early detection of AD, effective drug targeting to brain and theranostic (diagnosis and therapy) approaches in AD's management.

Indexed as

Theranostic NanomedicineAlzheimer DiseaseAnimalsDisease ManagementHumansAlzheimer's diseaseblood brain barrierdiagnosisnanomedicinesnanoparticlestheranostic

Identifiers

PMID28482786
PMCPMC5878045

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.